Optimization and clinical assessment of a radioreceptor assay for thyrotropin-binding inhibitor immunoglobulins.

We tried to improve the sensitivity of a radioreceptor assay for thyrotropin-binding inhibitor immunoglobulins (TBII) by modifying assay conditions. About a twofold increase in sensitivity without a loss of reproducibility was obtained by prolonging the incubation of the receptors with test serum from 15 to 120 min before the addition of 125I-labeled thyrotropin. In 20 untreated, 49 treated patients with Graves' disease and 19 patients with euthyroid Graves' disease, TBII activities obtained using 120 min preincubation were significantly higher than those obtained using 15 min preincubation (p less than 0.005). No significant increase in TBII activities was observed in the presence of sera from patients with primary hypothyroidism (n = 17), simple goiter (n = 7), adenomatous goiter (n = 11), thyroid adenoma (n = 11) or cancer (n = 12). TBII were detectable in 15 (47%) of 32 triiodothyronine-nonsuppressible Graves' patients who were receiving maintenance antithyroid drug therapy using 120 min preincubation, while they were positive in only 6 patients (19%) using 15 min preincubation. The assay using a longer preincubation period was found to be sensitive, specific and useful for diagnosis and follow-up of Graves' disease.

[1]  J. Konishi,et al.  Primary myxedema with thyrotrophin-binding inhibitor immunoglobulins. Clinical and laboratory findings in 15 patients. , 1985, Annals of Internal Medicine.

[2]  K. Burman,et al.  Immune mechanisms in Graves' disease. , 1985, Endocrine reviews.

[3]  H. Imura,et al.  Abnormal thyrotropin-binding immunoglobulins in two patients with Graves' disease. , 1984, The Journal of clinical endocrinology and metabolism.

[4]  B. Smith,et al.  A RECEPTOR ASSAY FOR THE MEASUREMENT OF TSH RECEPTOR ANTIBODIES IN UNEXTRACTED SERUM , 1984, Clinical endocrinology.

[5]  H. Ijichi,et al.  Characteristics of auto-antibodies to bovine TSH in the serum of two patients with Graves' disease. , 1983, Acta endocrinologica.

[6]  G. Beall,et al.  Binding of 125I-human TSH by gamma globulins of sera containing thyroid-stimulating immunoglobulin (TSI). , 1983, Life sciences.

[7]  B. Smith,et al.  AN IMPROVED RADIORECEPTOR ASSAY FOR TSH RECEPTOR ANTIBODIES , 1982, Clinical endocrinology.

[8]  J. Biró.  Thyroid-stimulating antibodies in Grave's disease and the effect of thyrotrophin-binding globulins on their determination. , 1982, The Journal of endocrinology.

[9]  H. Bliddal,et al.  Prognostic value of thyrotrophin binding inhibiting immunoglobulins (TBII) in longterm antithyroid treatment, 131I therapy given in combination with carbimazole and in euthyroid ophthalmopathy. , 1981, Acta endocrinologica.

[10]  T. Visser,et al.  THYROTROPHIN BINDING INHIBITING IMMUNOGLOBULINS IN GRAVES' DISEASE BEFORE, DURING AND AFTER ANTITHYROID THERAPY, AND ITS RELATION TO LONG‐ACTING THYROID STIMULATOR , 1980, Clinical endocrinology.

[11]  C. Teng,et al.  Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drug and its relationship to relapse: a prospective study. , 1980, The Journal of clinical endocrinology and metabolism.

[12]  R. Utiger,et al.  The natural history of hyperthyroidism due to Graves' disease in remission: sequential studies of pituitary-thyroid regulation and various serum parameters. , 1979, The Journal of clinical endocrinology and metabolism.

[13]  S. Nagataki,et al.  Correlation between thyroid stimulators and 3,5,3'-triiodothyronine suppressibility in patients during treatment for hyperthyroidism with thionamide drugs: comparison of assays by thyroid-stimulating and thyrotropin-displacing activities. , 1979, The Journal of clinical endocrinology and metabolism.

[14]  R. Volpe,et al.  Thyrotropin displacement activity of serum immunoglobulins from patients with Graves' disease. , 1978, The Journal of clinical endocrinology and metabolism.

[15]  J. Konishi,et al.  Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves' disease and Hashimoto's thyroiditis. , 1978, The Journal of clinical endocrinology and metabolism.

[16]  D. C. Evered,et al.  VALUE OF THYROID-STIMULATING-ANTIBODY DETERMINATIONS IN PREDICTING SHORT-TERM THYROTOXIC RELAPSE IN GRAVES' DISEASE , 1977, The Lancet.

[17]  D. Evered,et al.  THYROID‐STIMULATING IMMUNOGLOBULINS IN OPHTHALMIC GRAVES'DISEASE , 1977, Clinical endocrinology.

[18]  J. Mckenzie,et al.  LATS in Graves' disease. , 1976, Recent progress in hormone research.

[19]  B. Smith,et al.  THYROID-STIMULATING IMMUNOGLOBULINS IN GRAVES' DISEASE , 1974 .

[20]  D Rodbard,et al.  Mathematical analysis of kinetics of radioligand assays: improved sensitivity obtained by delayed addition of labeled ligand. , 1971, The Journal of clinical endocrinology and metabolism.